Benzinga · Mar 11, 2026
KA
NASDAQ · KALA
KALA BIO, Inc.
Healthcare · Biotechnology
$0.52
Up+$0.01 (+2.74%)
Updated Sep 17, 2026, 5:16 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 4.82M
- P/E ratio
- -0.13
- Dividend yield
- 0.00%
- 52-week range
- $0.10 – $20.60
- Volume
- 174.42K
- Avg. volume
- 7.81M
Price performance
KALA price history
1M range · 0 trading sessions · Daily adjusted prices
KALA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest KALA news
The latest Smart Investors Daily articles mentioning KALA.
Stock researchCompany · Overview
KALA research
Overview
Company profile and research snapshot.
Company profile
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $18.25
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2025 | HC Wainwright & Co. | Neutral | — |
| Sep 17, 2025 | HC Wainwright & Co. | Buy | — |
| Sep 11, 2025 | Oppenheimer | Outperform | — |
| Sep 8, 2025 | Mizuho | Outperform | — |
| May 23, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 11, 2026
Kala Bio Chases 'Palantir For Biotech' Dream With New AI Platform
Is KALA the Palantir of biotech? Kala Bio Inc. pivots to agentic AI with a new platform shipping in 2 weeks. Read the full update.
Benzinga · Mar 11, 2026
Kala Bio Said It Is Ready To Ship Its First Commercial AI Product In Approximately 14 Days, As It Targets The $180+ Billion AI-In-Healthcare Market
Kala is building the Palantir for biotech, just as Palantir built a $250+ billion company by helping governments and enterprises make sense of massive data, Kala is doing the same for the biotech and pharmaceutical
Benzinga · Mar 4, 2026
KALA BIO Eyes Pharma R&D Spend With Secure AI Licensing Model
KALA BIO (KALA) shares rose after unveiling a strategic initiative to build an on-premises AI infrastructure platform for biotech.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
